112 related articles for article (PubMed ID: 8471446)
1. Advanced breast cancer: use of resources and cost implications.
Richards MA; Braysher S; Gregory WM; Rubens RD
Br J Cancer; 1993 Apr; 67(4):856-60. PubMed ID: 8471446
[TBL] [Abstract][Full Text] [Related]
2. Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation study.
de Kok M; Frotscher CN; van der Weijden T; Kessels AG; Dirksen CD; van de Velde CJ; Roukema JA; Bell AV; van der Ent FW; von Meyenfeldt MF
BMC Cancer; 2007 Jul; 7():117. PubMed ID: 17605796
[TBL] [Abstract][Full Text] [Related]
3. Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 110 hospital admissions.
Menzies D; Parker M; Hoare R; Knight A
Ann R Coll Surg Engl; 2001 Jan; 83(1):40-6. PubMed ID: 11212449
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer management: quality-of-life and cost considerations.
Radice D; Redaelli A
Pharmacoeconomics; 2003; 21(6):383-96. PubMed ID: 12678566
[TBL] [Abstract][Full Text] [Related]
5. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
7. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
8. Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London.
Bryan S; Brown J; Warren R
J Epidemiol Community Health; 1995 Feb; 49(1):70-8. PubMed ID: 7707010
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a short stay admission programme for breast cancer surgery.
de Kok M; Dirksen CD; Kessels AG; van der Weijden T; van de Velde CJ; Roukema JA; Bell AV; van der Ent FW; von Meyenfeldt MF
Acta Oncol; 2010 Apr; 49(3):338-46. PubMed ID: 20397768
[TBL] [Abstract][Full Text] [Related]
10. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.
Guest JF; Cookson RF
Pharmacoeconomics; 1999 Jun; 15(6):597-610. PubMed ID: 10538332
[TBL] [Abstract][Full Text] [Related]
11. Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database.
Fisher MD; Fernandes AW; Olufade TO; Miller PJ; Walker MS; Fenton M
Clin Ther; 2018 Apr; 40(4):562-573. PubMed ID: 29530457
[TBL] [Abstract][Full Text] [Related]
12. Metastatic breast cancer: we do need primary cost data.
Bonastre J; Jan P; Barthe Y; Koscielny S
Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
14. The total hospital and community UK costs of managing patients with relapsed breast cancer.
Thomas RJ; Williams M; Marshall C; Glen J; Callam M
Br J Cancer; 2009 Feb; 100(4):598-600. PubMed ID: 19223909
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.
Boer R; de Koning H; Threlfall A; Warmerdam P; Street A; Friedman E; Woodman C
BMJ; 1998 Aug; 317(7155):376-9. PubMed ID: 9694752
[TBL] [Abstract][Full Text] [Related]
16. Economic outcomes of breast cancer survivorship: CALGB study 79804.
Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E
Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443
[TBL] [Abstract][Full Text] [Related]
17. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.
Karnon J; Kerr GR; Jack W; Papo NL; Cameron DA
Br J Cancer; 2007 Aug; 97(4):479-85. PubMed ID: 17653077
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial.
Jones J; Wilson A; Parker H; Wynn A; Jagger C; Spiers N; Parker G
BMJ; 1999 Dec; 319(7224):1547-50. PubMed ID: 10591720
[TBL] [Abstract][Full Text] [Related]
19. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
20. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
